Part 1 of 2:
Actually, the reality on the ground is just a teeny bit different.
The importation of drugs from Canada to the US, for cost containment, has been blocked by PhRMA (the US drug industry lobbyists) for years. They insist Canada's QC is inferior, which is a laugh, because many drug firms have manufacturing facilities in Canada and routinely import products from these sites for sale in the US - with FDA approval to do so.
And did I mention that Canada's GMP requirements (that's pharmaceutical Good Manufacturing Practices) are more stringent than those of the USA?
Here's a bit of information from the Regulatory Affairs Professionals' Society about Canada's pricing system. (That's drug (and biologics) and device regulators, and the organization is international). It's a bit geeky, but the bottom line is that Canada has been looking at US drug prices as a comparator for cost containment, among others, and now intends to drop the US comparisons and look at a wider cross section of countries' prices. Because using the US as an index has resulted in systematic overpricing in Canada.
Quote:
Canada’s System and Proposal
Currently, the country’s Patented Medicine Prices Review Board (PMPRB) compares Canada’s prices with seven other countries, including the US, to determine if it is over-paying. But the proposal would no longer use the US or Switzerland as comparators and would add seven other countries: Australia, Belgium, Japan, Netherlands, Norway, South Korea and Spain.
The proposal also would use three new factors when determining whether a medicine is being or has been sold at an excessive price: A pharmacoeconomic evaluation for a medicine with a fixed cost per quality-adjusted life year (QALY) threshold in Canada, the size of the market for the drug in Canada and in other markets, and the gross domestic product of Canada.
"When the Regulations were first conceived 30 years ago, policy makers believed that patent protection and price were key drivers of pharmaceutical R&D investment. The choice was thus made to offer a comparable level of patent protection and pricing for drugs as exists in countries with a strong pharmaceutical industry presence, on the assumption that Canada would come to enjoy comparable levels of R&D. However, the percentage of R&D-to-sales by pharmaceutical patentees in Canada has been falling since the late 1990s and is at a historic low. By comparison, and despite Canada having among the highest patented drug prices, industry R&D investment relative to sales in the PMPRB7 countries is on average 22.8% versus 4.4% in Canada," the proposal says.
Taken from this article:
https://www.raps.org/news-articles/news ... egulationsArticle dates from May of 2017, so if any of our Canadian members have more recent news, please share.
_________________
"I believe you find life such a problem because you think there are the good people and the bad people," said the man. "You're wrong, of course. There are, always and only, the bad people, but some of them are on opposite sides."
-- Terry Pratchett, Guards! Guards!
Last edited by Esmerelda Weatherwax on 18 Feb 2018, 1:40 pm, edited 2 times in total.